Bladder Cancer

Immune-related adverse effects may show significantly longer progression-free survival and overall survival in patients with metastatic urothelial carcinoma who are receiving pembrolizumab.

Sophia Kamran, MD, discusses the research supporting the use of trimodality therapy with immunotherapy for patients with urothelial cancer.

Matthew Galsky, MD, discussed the DS8201-A-U105 trial of T-DXd plus nivolumab in patients with HER2-expressing urothelial cancer.

Nintedanib plus neoadjuvant chemotherapy did not achieve improvement in pathologic complete response in patients with muscle invasive bladder cancer in the phase 2 NEOBLADE study, but the study provided important survival signals.

Adding pembrolizumab to CG0070 led to a complete response rate of 88.9% among 18 patients in the phase 2 CORE1 trial.

Tracy Rose, MD, discusses the promising outlook of the current bladder cancer space.

The phase 1 ADVANCED-1 trial of the biologic immunopotentiator agent TARA-002 began dosing patients with non-muscular invasive bladder cancer.

During a Targeted Oncology case-based roundtable event, Arlene Siefker-Radtke discussed the second-line treatment options for a patient with urothelial carcinoma and the EV-301 trial of enfortumab vedotin.

Following the important information provided by the phase 3 VESPER trial, Jean Hoffman-Censits, Md said there are several noteworthy ongoing phase 3 neoadjuvant immunotherapy studies in bladder cancer.

Daniel P. Petrylak, MD, discusses the targeted therapies that have shown encouraging results in patients with metastatic urothelial cancer.

Sophia Kamran, MD, discusses the research supporting the use of trimodality therapy for patients with urothelial cancer.

Tracy Rose, MD, discussed the future of adjuvant and neoadjuvant therapy in muscle-invasive bladder cancer specifically using cisplatin-based regimens.

In recent years, the field of metastatic urothelial cancer has seen many new immunotherapy agents and targeted therapies that have improved patient outcomes.

Tracy L. Rose, MD, MPH, discusses ongoing research in bladder cancer that aims to add onto the standard of care and improve patient outcomes.

In an interview with Targeted Oncology, Sophia Kamran, MD, discussed the effectiveness of trimodality therapy as well as other novel therapeutics in patients with bladder cancer.

Patients with muscle invasive bladder cancer ineligible for cisplatin in cohort H of the phase 1b/2 EV-103 trial demonstrated promising antitumor activity when receiving neoadjuvant enfortumab vedotin.

The phase 2 BAYOU study failed to meet its primary end point of improvement in progression-free survival with olaparib plus durvalumab in patients with platinum-ineligible metastatic urothelial carcinoma.

Patients with checkpoint inhibitor–naïve metastatic urothelial cancer had promising anti-tumor activity when treated with sacituzumab govitecan and pembrolizumab in the second-line setting.

Mixed results were reported from the phase 2 ARIES clinical trial at the 2022 ASCO GU meeting.

Patients with urothelial cancer whose tumors overexpress c-Met may benefit from this unique combination.

An exploratory analysis of the phase 3 JAVELIN Bladder 100 trial shows that the overall survival benefit of frontline maintenance avelumab is sustained in patients with advanced urothelial cancer.

Results from the combination of lenvatinib and pembrolizumab show similarity with the comparator in the phase 3 LEAP-011 study.

Much has changed in the understanding and treatment of urothelial cancer and questions are addressed in the updated ESMO clinical practice guidelines.

A novel gene therapy is being investigated for the treatment of Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, and the preliminary findings signal a high response rate with little toxicity.

Investigation of intravesical checkpoint-targeted therapy may warrant further investigation in patients with BCG-unresponsive bladder cancer.